Abstract #4336
Advanced imaging in lesion and normal-appearing white matter over 2 years in MS patients treated with alemtuzumab
Irene Vavasour 1 , Alex MacKay 1,2 , David Li 1 , Cornelia Laule 1,3 , and Anthony Traboulsee 4
1
Radiology, University of British Columbia,
Vancouver, British Columbia, Canada,
2
Physics
and Astronomy, University of British Columbia,
Vancouver, British Columbia, Canada,
3
Pathology
and Laboratory Medicine, University of British Columbia,
Vancouver, British Columbia, Canada,
4
Medicine,
University of British Columbia, Vancouver, British
Columbia, Canada
Alemtuzumab is a multiple sclerosis (MS) therapy
designed to inhibit inflammation and prevent the
accumulation of disability. To test the potential
neuroprotective properties of the drug, we used advanced
MRI to monitor changes in myelin water fraction, T2 and
T1 within lesions and normal-appearing white matter over
2 years in MS patients treated with alemtuzumab. Data
suggests that, while on treatment, remyelination appears
more robust possibly due to an improved immunologic
milieu 6 months post-alemtuzumab. Supporting this is a
smaller T1 increase at new lesion appearance indicating
less edema and inflammation for lesions formed while
under the effects of alemtuzumab.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
